NextCure, Inc.

Introduction

This page provides a comprehensive analysis of the known insider trading history of Michael Richman. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Michael Richman has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:NXTC / NextCure, Inc. President & CEO, Director 262,400
US:PIRS / Pieris Pharmaceuticals, Inc. Director 40,000
US:GNVC / GenVec, Inc. Director 0
US:OPXA / Opexa Therapeutics, Inc. Director 25,884
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Michael Richman. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases NXTC / NextCure, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in NXTC / NextCure, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NXTC / NextCure, Inc. Insider Trades
Insider Sales NXTC / NextCure, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in NXTC / NextCure, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NXTC / NextCure, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Michael Richman as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2022-02-02 2022-01-31 4 NXTC NextCure, Inc.
Employee Stock Option (Right to Buy)
A - Award 262,400 262,400
2021-06-29 2021-06-25 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 40,000 40,000
2021-03-16 2021-03-15 4 NXTC NextCure, Inc.
Employee Stock Option (Right to Buy)
A - Award 300,000 300,000
2020-06-25 2020-06-23 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 40,000 40,000
2020-03-03 2020-02-28 4 NXTC NextCure, Inc.
Employee Stock Option (Right to Buy)
A - Award 225,000 225,000
2020-01-28 2020-01-25 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 20,000 20,000
2020-01-28 2020-01-25 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 5,431 5,431 2.11 11,443 11,443
2019-10-28 2019-10-25 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Options (right to buy)
A - Award 5,165 5,165 2.12 10,939 10,939
2019-07-26 2019-07-25 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 3,789 3,789 2.89 10,950 10,950
2019-05-08 3 NXTC NextCure, Inc.
Common Stock
771,738
2019-05-08 3 NXTC NextCure, Inc.
Common Stock
771,738
2019-05-08 3 NXTC NextCure, Inc.
Common Stock
771,738
2019-04-30 2019-04-25 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 5,640 5,640 1.94 10,942 10,942
2019-01-29 2019-01-25 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 20,000 20,000
2019-01-29 2019-01-25 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 6,096 6,096 1.79 10,912 10,912
2018-10-29 2018-10-25 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 3,829 3,829 2.86 10,951 10,951
2018-07-26 2018-07-25 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 2,837 2,837 3.86 10,951 10,951
2018-04-26 2018-04-25 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 2,665 2,665 4.10 10,926 10,926
2018-01-29 2018-01-25 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 20,000 20,000
2018-01-29 2018-01-25 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 2,243 2,243 5.09 11,417 11,417
2017-10-27 2017-10-25 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (Rights to buy)
A - Award 4,006 4,006
2017-07-27 2017-07-25 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 3,288 3,288
2017-06-20 2017-06-16 4 GNVC GENVEC INC
Stock Options (right to buy)
M - Exercise -2,250 0 -100.00 3.80 -8,550
2017-06-20 2017-06-16 4 GNVC GENVEC INC
Common Stock
D - Sale to Issuer -1,061 0 -100.00
2017-06-20 2017-06-16 4 GNVC GENVEC INC
Common Stock
F - Taxes -1,189 1,061 -52.84 7.19 -8,549 7,629
2017-06-20 2017-06-16 4 GNVC GENVEC INC
Common Stock
M - Exercise 2,250 2,250 3.80 8,550 8,550
2017-04-27 2017-04-25 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 7,821 7,821
2017-01-30 2017-01-25 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 20,000 20,000
2017-01-30 2017-01-25 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 9,687 9,687
2016-10-27 2016-10-25 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 9,656 9,656
2016-10-24 2016-10-20 4 GNVC GENVEC INC
Stock Options (right to buy)
A - Award 22,500 22,500
2016-10-04 2016-09-30 4 OPXA Opexa Therapeutics, Inc.
Common Stock
A - Award 6,455 25,884 33.22
2016-08-01 2016-07-25 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 9,144 9,144
2016-07-01 2016-06-30 4 OPXA Opexa Therapeutics, Inc.
Common Stock
A - Award 6,455 19,429 49.75
2016-05-18 2016-05-16 4 OPXA Opexa Therapeutics, Inc.
Common Stock
A - Award 6,455 12,974 99.02
2016-04-29 2016-04-27 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 7,679 7,679
2016-02-18 2016-02-16 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 20,000 20,000
2016-01-20 2016-01-15 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 9,654 9,654
2016-01-04 2015-12-31 4 OPXA Opexa Therapeutics, Inc.
Common Stock
A - Award 1,354 6,520 26.21
2015-11-16 2015-11-13 4 GNVC GENVEC INC
Stock Options (right to buy)
A - Award 15,000 15,000
2015-10-30 2015-10-15 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 8,267 8,267
2015-10-02 2015-09-30 4 OPXA Opexa Therapeutics, Inc.
Common Stock
A - Award 1,200 5,166 30.26
2015-07-17 2015-07-15 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 6,310 6,310
2015-07-01 2015-06-30 4 OPXA Opexa Therapeutics, Inc.
Common Stock
A - Award 8,427 31,729 36.16
2015-04-22 2015-04-21 4 GNVC GENVEC INC
Stock Options (right to buy)
A - Award 20,000 20,000
2015-04-09 2015-04-08 4 OPXA Opexa Therapeutics, Inc.
Warrants (Right to Buy)
M - Exercise 8,242 8,242
2015-04-09 2015-04-08 4 OPXA Opexa Therapeutics, Inc.
Subscription Rights (Right to Buy)
M - Exercise -8,242 0 -100.00
2015-04-09 2015-04-08 4 OPXA Opexa Therapeutics, Inc.
Common Stock
M - Exercise 8,242 23,302 54.73
2015-04-01 2015-03-31 4 OPXA Opexa Therapeutics, Inc.
Common Stock
A - Award 6,818 15,060 82.72
2015-04-01 2015-03-30 4 OPXA Opexa Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 23,804 23,804
2015-04-01 2015-03-30 4 OPXA Opexa Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 71,410 71,410
2014-03-04 2014-02-28 4 OPXA Opexa Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 5,896 5,896
2014-03-04 2014-02-28 4 OPXA Opexa Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 17,686 17,686
2014-03-04 2014-02-28 4 OPXA Opexa Therapeutics, Inc.
Common Stock
A - Award 8,242 8,242
2013-05-01 2013-04-29 4 OPXA Opexa Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 17,143 17,143
2013-05-01 2013-04-29 4 OPXA Opexa Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 5,000 5,000
2012-03-05 2012-03-01 4 OPXA Opexa Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 20,600 20,600
2012-03-05 2012-03-01 4 OPXA Opexa Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 10,000 10,000
2010-05-05 2010-04-30 4 OPXA Opexa Therapeutics, Inc.
Common Stock Option (right to buy)
A - Award 7,889 7,889
2010-05-05 2010-04-30 4 OPXA Opexa Therapeutics, Inc.
Common Stock Option (right to buy)
A - Award 10,000 10,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)